Moyad Shahwan
Overview
Explore the profile of Moyad Shahwan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
716
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jairoun A, Al-Hemyari S, El-Dahiyat F, Shahwan M, Zyoud S, Jeroudy H, et al.
J Am Pharm Assoc (2003)
. 2025 Mar;
:102386.
PMID: 40058497
Background: The importance of collaboration between physicians and community pharmacists in healthcare is increasingly recognized. Enhanced cooperation positively impacts medication management and patient outcomes by merging medical and pharmaceutical expertise...
2.
Hussain M, Goyal A, Goyal K, S R, Nellore J, Shahwan M, et al.
Naunyn Schmiedebergs Arch Pharmacol
. 2025 Mar;
PMID: 40047857
Inflammatory lung diseases (ILDs) such as asthma, acute respiratory distress syndrome, bronchiectasis, chronic obstructive pulmonary disease, COVID-19, cystic fibrosis, and lung cancer impose a substantial worldwide healthcare impact. The pathophysiology...
3.
Jairoun A, Al-Hemyari S, Shahwan M, Alnuaimi G, Ibrahim N, Jaber A
Explor Res Clin Soc Pharm
. 2025 Mar;
16:100518.
PMID: 40046775
Objectives: To investigate the pharmacists' perspectives on benefits and risks of using ChatGPT in pharmacy practice and explore how this disruptive and ground-breaking technology can be effectively integrated. Methods And...
4.
Towards eco-friendly pharmaceuticals: Regulatory and policy approaches for sustainable medicines use
Jairoun A, Al-Hemyari S, Shahwan M, Alkhoujah S, El-Dahiyat F, Jaber A, et al.
Explor Res Clin Soc Pharm
. 2025 Mar;
17:100576.
PMID: 40026320
Objectives: The current study aimed to investigate how regulatory frameworks and policies are used to support the use of sustainable medicines within the pharmaceutical sector. Methods: The Scopus database was...
5.
Zyoud S, Taha S, Zyoud S, Shahwan M, Jairoun A, Al-Jabi S
Lasers Med Sci
. 2025 Feb;
40(1):88.
PMID: 39948328
Conventional acne treatments are associated with side effects from medication and antibiotic resistance, leading to the search for alternative therapeutic modes of action, such as lasers. The considered bibliometric and...
6.
Zyoud S, Shahwan M, Jairoun A
Aesthetic Plast Surg
. 2025 Jan;
PMID: 39870929
No abstract available.
7.
Jairoun A, Ping C, Ibrahim B, Al Jawamis D, Al Jaberi A, Dawoud T, et al.
J Pharm Policy Pract
. 2025 Jan;
18(1):2414293.
PMID: 39776464
Background: Chronic Kidney Disease (CKD) represents a significant worldwide health challenge, with far-reaching implications for both patients and healthcare systems. This study aimed to identify the incidence of CKD at...
8.
Alrouji M, Yasmin S, Alshammari M, Alhumaydhi F, Sharaf S, Shahwan M, et al.
PLoS One
. 2025 Jan;
20(1):e0316343.
PMID: 39752394
Epigenetic processes are the critical events in carcinogenesis. Histone modification plays a crucial role in gene expression regulation, where histone deacetylases (HDACs) are key players in epigenetic processes. Inhibiting HDACs...
9.
Goyal K, Afzal M, Altamimi A, Babu M, Ballal S, Kaur I, et al.
Biogerontology
. 2024 Dec;
26(1):32.
PMID: 39725742
Chronic kidney diseases (CKD) are a group of multi-factorial disorders that markedly impair kidney functions with progressive renal deterioration. Aging contributes to age-specific phenotypes in kidneys, which undergo several structural...
10.
Alrouji M, Yasmin S, Alshammari M, Alhumaydhi F, Sharaf S, Shahwan M, et al.
PLoS One
. 2024 Dec;
19(12):e0316010.
PMID: 39700174
Alzheimer's disease (AD) is characterized by the aggregation of amyloid β (Aβ) peptides and the formation of plaques in the brain, primarily derived from the proteolytic degradation of amyloid precursor...